Alphamab Oncology (HKG:9966) presented the results of a phase 1/2 study of its JSKN033 treatment during a cancer immunotherapy summit in Houston, according to a Sunday filing with the Hong Kong Exchange.
JSKN033 is indicated for HER2-expressing advanced or metastatic solid tumors.
The study showed favorable anti-tumor activity while exhibiting safety, the filing said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。